Last reviewed · How we verify

NCT03357861: IMMUNO-REA

Cancer Patients Treated With Immunotherapy in Intensive Care Unit

Completed Last updated 26 October 2021
What this trial tests

trial in Cancer in 100 participants. Completed in 23 August 2021.

Timeline
1 September 2018
Primary endpoint
23 August 2021
23 August 2021

Quick facts

Lead sponsorUniversity Hospital, Grenoble
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date1 September 2018
Primary completion23 August 2021
Estimated completion23 August 2021
Sites2 locations across Belgium, France

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

18 and older, any sex, with Cancer or Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This work aims to describe the characteristics and methods of management of patients suffering from a solid tumor treated with immunotherapy admitted to intensive care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. ICU admission for solid cancer patients treated with immune checkpoint inhibitors.
    Toffart AC, Meert AP, Wallet F, Gibelin A, et al · · 2023 · cited 12× · PMID 37072645 · DOI 10.1186/s13613-023-01122-z

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03357861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing